EVAX
Evaxion A/S
stockNASDAQADR
since 2008, evaxion biotech has been pioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence, with the mission to solve some of the world's most significant challenges to human health. evaxion has constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, pioneer and eden. using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. eden enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while pioneer has been constructed to identify the epitopes of mutated proteins that will fire up the body's natural immune responses to them. to learn more about evaxion, please visit http://www.evaxion-biotech.ai
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.08 | 2026-10-26 | -4.54% | 2.269 |
| 1M | 3.20 | 2026-10-02 | -8.13% | 0.402 |
| 3M | 2.79 | 2026-08-03 | +5.38% | 1.049 |
| 6M | 4.50 | 2026-05-01 | -34.59% | 0.736 |
| 1Y | 5.77 | 2025-11-03 | -49.05% | 0.527 |
| 2Y | 12.95 | 2024-11-01 | -77.30% | — |
| 5Y | 364.50 | 2021-11-02 | -99.19% | 0.611 |
Evaxion A/S (NASDAQ:EVAX) stock price today is $2.94, and today's volume is 19,516. EVAX is up 0.341% today. The 30 day average volume is 98,417. EVAX market cap is $26.52M with 9.02M shares outstanding.